A Phase 3, Multi-Center, Open-Label Randomized Study of Oral Asciminib Versus Bosutinib in Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or more Tyrosine Kinase Inhibitors
The purpose of this study is to compare the benefits and side effects of ABL001 versus bosutinib in patients with CML in chronic phase.
Chronic Myelogenous Leukemia in chronic phase (CML-CP)
- Men and women at least 18 years of age
- Clinically diagnosed with CML
- Have previously been treated with at least two tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, dasatinib, radotinib or ponatinib
- No previous treatment with a hematopoietic stem-cell transplantation
18 - 99
Healthy Volunteers Needed
Duration of Participation
Participants will receive study treatment for up to 3 years. After you finish the study treatment, the investigator will continue to watch you for side effects and follow your condition for up to 5 years from the date the last patient received the first study dose.
Clinical Trials Information Line